ABNewswire - Press Release Distribution Service

Monday, May 31, 2021

Vitiligo Market Analysis, Market Size, Epidemiology, Trends, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP

DelveInsight's "Vitiligo–Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Vitiligo, historical and forecasted epidemiology as well as the Vitiligo market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on "Vitiligo-Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Vitiligo–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Vitiligo, historical and forecasted epidemiology as well as the Vitiligo market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

DelveInsight’s epidemiology model suggests that overall, female population was found to be more prevalent than male population.
The total prevalent population of Vitiligo in the seven major markets was approximately 6,234,655 in 2017.
The United States accounted for the highest prevalent cases with around 2,663,753 prevalent cases in 2017, followed by Japan (approximately 2,141,164 cases) and EU5.
Among the European countries, Germany has the highest prevalent population with approximately 472,057 cases followed by the UK which has prevalent population of approximately 290,965 in 2017.
France has the lowest number of prevalent cases, among EU-5 countries, with around 188,196 cases in 2017.

Key benefits of the report:

1.The Vitiligo market report covers a descriptive overview and comprehensive insight of the Vitiligo epidemiology and Vitiligo market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.The Vitiligo market report provides insights into the current and emerging therapies.

3.Vitiligo market report provides a global historical and forecasted market covering drug outreach in 7MM.

4.The Vitiligo market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Vitiligo market.

Request for sample pages: https://www.delveinsight.com/sample-request/vitiligo-market

Vitiligo: Overview

Vitiligo is a disease that causes the loss of skin color in patches. Colored areas usually grow over time. The condition can affect the skin on any part of the body. It can also affect the hair and the inside of the mouth.

Usually, hair and skin color are determined by melanin. Vitiligo occurs when cells that produce melanin die or stop functioning. Vitiligo affects people of all skin types, but can be most noticeable in people with darker skin. The condition is not life threatening or contagious. It can be stressful or can make you feel bad about yourself.

Treatment for vitiligo can restore color to the affected skin. But it does not prevent further loss of skin color or recurrence.

The key players involved in the Vitiligo market:

1. Incyte Corporation

2. Clinuvel Pharmaceutical

The launch of the emerging therapies is expected to significantly impact the Vitiligo treatment scenario in the upcoming years:-

Drug covered

INCB018424
SCENESSE (afamelanotide)

Request a free sample report @https://www.delveinsight.com/sample-request/vitiligo-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Vitiligo Patient Share (%) Overview at a Glance

5. Vitiligo Market Overview at a Glance

6. Vitiligo Disease Background and Overview

7. Vitiligo Epidemiology and Patient Population

8. Country-Specific Patient Population of Vitiligo

9. Vitiligo Current Treatment and Medical Practices

10. Unmet Needs

11. Vitiligo Emerging Therapies

12. Vitiligo Market Outlook

13. Country-Wise Vitiligo Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Vitiligo Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Vitiligo-Pipeline Insights, 2021

"Vitiligo-Pipeline Insight, 2021" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Vitiligo market. A detailed picture of the Vitiligo pipeline landscape is provided, which includes the disease overview and Vitiligo treatment guidelines.

Vitiligo-Epidemiology Forecast to 2030

DelveInsight's 'Vitiligo-Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Vitiligo{;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.www.delveinsight.com/report-store/vitiligo-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Pancreatic Cancer Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP

DelveInsight's "Pancreatic Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pancreatic Cancer, historical and forecasted epidemiology as well as the Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on "Pancreatic Cancer-Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Pancreatic Cancer–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of Pancreatic Cancer, historical and forecasted epidemiology as well as the Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

According to a study in 2018, 458,918 new cases of pancreatic cancer were registered worldwide, representing 2.5% of all cancers. The age-standardized rate (ASR) incidence was highest in Europe (7.7 per 100,000 people) and North America (7.6 per 100,000 people). A slight difference in pancreatic cancer incidence among genders was observed. It was more common in men (5.5 per 100,000, 243,033 cases) than in women (4.0 per 100,000, 215,885 cases). The incidence rate for both sexes increases with age. Pancreatic cancer was seldom diagnosed before 55 years of age, and it can be defined as a disease of elderly populations because the highest incidence is reported in people over 70 years.
According to the observation, there were 53,265 patients diagnosed with pancreatic cancer in England between 1998 and 2006. Around 411 patients were aged between 20 and 39, which equated to an average of 23 cases per year. There were less than 50 cases per year for those in their 30s and an average of 185 per year for those in their 40s. The age-specific incidence of pancreatic cancer increased with age and was highest in males and females aged over 80. The incidence remained stable in all age groups over 50, except for females aged 50-59 where there was a slight increase in incidence (p =0.039).

Key benefits of the report:

1.The Pancreatic Cancer market report covers a descriptive overview and comprehensive insight of the Pancreatic Cancer epidemiology and Pancreatic Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.The Pancreatic Cancer market report provides insights into the current and emerging therapies.

3.Pancreatic Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.

4.The Pancreatic Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Pancreatic Cancer market.

Request for sample pages: https://www.delveinsight.com/sample-request/pancreatic-cancer-market

Pancreatic Cancer: Overview

Pancreatic adenocarcinoma is one of the most aggressive forms of cancer and is projected to arise as the second leading cause of cancer-related deaths in Europe and the United States shortly. In the US, pancreatic cancer is the 9th or 10th most commonly diagnosed cancer (depending on gender).

A clinical/radiographic stage classification for pancreatic cancer suggests a three-stage classification (potentially resectable, locally advanced, and advanced) of pancreatic cancer involvement based on radiological findings.

The key players involved in the Pancreatic Cancer market:

FibroGen
SynCore Biotechnology
Galera Therapeutics
Singh Biotechnology
AB Science
AstraZeneca
NanOlogy
NantKwest/ImmunityBio
Rafael Pharmaceuticals

The launch of the emerging therapies is expected to significantly impact the Pancreatic Cancer treatment scenario in the upcoming years:-

Drug covered

Pamrevlumab (Anti CTGF antibody)
EndoTAG-1 (ET)
GC4419
SBT-100
Masitinib
AZD6738
NanoPac
PD-L1 t-hank and N-803
CPI-613 (devimistat)

Request a free sample report @https://www.delveinsight.com/sample-request/pancreatic-cancer-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Pancreatic Cancer Patient Share (%) Overview at a Glance

5. Pancreatic Cancer Market Overview at a Glance

6. Pancreatic Cancer Disease Background and Overview

7. Pancreatic Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Pancreatic Cancer

9. Pancreatic Cancer Current Treatment and Medical Practices

10. Unmet Needs

11. Pancreatic Cancer Emerging Therapies

12. Pancreatic Cancer Market Outlook

13. Country-Wise Pancreatic Cancer Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Pancreatic Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Pancreatic Cancer-Pipeline Insights, 2021

"Pancreatic Cancer-Pipeline Insight, 2021" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Pancreatic Cancer market. A detailed picture of the Pancreatic Cancer pipeline landscape is provided, which includes the disease overview and Pancreatic Cancer treatment guidelines.

Pancreatic Cancer-Epidemiology Forecast to 2030

DelveInsight's 'Pancreatic Cancer-Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Pancreatic Cancer{;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Fabry disease Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP

DelveInsight's "Fabry Disease - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on "Fabry disease-Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Fabry disease–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Fabry disease, historical and forecasted epidemiology as well as the Fabry disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

According to National Organization for Rare Diseases (NORD), It is estimated that type 1 classic Fabry disease affects approximately one in 40,000 males. The type 2 later-onset phenotype is more frequent than the type 1 phenotype by 3-10 fold, and in some populations may occur as frequently as about 1 in 1,500 to 4,000 males.
US estimate for Fabry disease described in the National Institutes of Health Genetics Home Reference states Fabry disease affects an estimated 1 in 40,000 to 60,000 males.
In a study by Colon et al, 2017 newborn screening for Fabry disease performed on the Spanish population revealed a prevalence of genetic alterations in GLA of 0.1% in males (0.013% with classic Fabry disease)
In a study by Doheny et al, 2018 prevalence estimates: among 36820 (23954M and 12866F) haemodialysis screenees, 0.21% males and 0.15% females; among 3074 (2031M and 1043F) renal transplant screenees, 0.25% males and no females; among 5491 (4054M and 1437F) cardiac screenees, 0.94% males and 0.90% females; and among 5978 (3904M and 2074F) stroke screenees, 0.13% males and 0.14% females. Among male and female screenees with pathogenic mutations, the type 1 Classic phenotype was predominant (~60%), except more male cardiac patients (75%) had type 2 Later-Onset phenotype.

Key benefits of the report:

1.The Fabry disease market report covers a descriptive overview and comprehensive insight of the Fabry disease epidemiology and Fabry disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.The Fabry disease market report provides insights into the current and emerging therapies.

3.Fabry disease market report provides a global historical and forecasted market covering drug outreach in 7MM.

4.The Fabry disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Fabry disease market.

Request for sample pages: https://www.delveinsight.com/sample-request/fabry-disease-market

Fabry disease: Overview

Fabry disease (FD) is a devastating, progressive, inherited condition caused by lysosomal dysfunction linked to chromosome X and mutations in the GLA gene located in chromosome Xq22.1 which encodes the alpha-galactosidase A (AGA) enzyme.

It is a multi-systemic and life-threatening condition that is one of the most common lysosomal storage diseases after the Gaucher Disease. It is characterized by specific neurological, cutaneous, renal, cardiovascular, cochleovestibular, and cerebrovascular manifestations. The symptoms include Chronic pain, usually a burning or tingling sensation in the hands and feet. The pain sometimes briefly becomes more intense, requiring medication to bring it down to manageable levels.

The key players involved in the Fabry disease market:

Safoni Genzyme
Idorsia Pharmaceuticals
Protalix Biotherapeutics
Sangamo Therapeutics
4D MolecularTherapeutics

The launch of the emerging therapies is expected to significantly impact the Fabry disease treatment scenario in the upcoming years:-

Drug covered

Venglustat
Lucerastat
PRX- 102
ST 920
4D-310

Request a free sample report @https://www.delveinsight.com/sample-request/fabry-disease-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Fabry disease Patient Share (%) Overview at a Glance

5. Fabry disease Market Overview at a Glance

6. Fabry disease Disease Background and Overview

7. Fabry disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Fabry disease

9. Fabry disease Current Treatment and Medical Practices

10. Unmet Needs

11. Fabry disease Emerging Therapies

12. Fabry disease Market Outlook

13. Country-Wise Fabry disease Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Fabry disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Fabry disease-Pipeline Insights, 2021

"Fabry disease-Pipeline Insight, 2021" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Fabry disease market. A detailed picture of the Fabry disease pipeline landscape is provided, which includes the disease overview and Fabry disease treatment guidelines.

Fabry disease-Epidemiology Forecast to 2030

DelveInsight's 'Fabry disease-Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Fabry disease{;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Fabry Disease-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

"Fabry Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report by DelveInsight offers comprehensive insights on marketed and Phase III products for Fabry Disease. The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2023. It further provides the marketed products API manufacturer details for United States, Europe, China, and India.

Xerostomia Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP

DelveInsight's "Xerostomia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Xerostomia, historical and forecasted epidemiology as well as the Xerostomia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on "Xerostomia-Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Xerostomia–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Xerostomia, historical and forecasted epidemiology as well as the Xerostomia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

According to the study prevalence of xerostomia was 16% (patients with XI scores 10) and the prevalence of hyposalivation was 31% (patients with stimulated salivary flow rate 0.7 ml/min).
According to the observation that the prevalence of xerostomia ranged from 17% to 40% among community-dwelling elders and 20% to 72% among institutionalized elders. The prevalence of hyposalivation ranged from 15% to 23% in the community-dwelling elders and 17% to 50% among institutionalized elders
According to the observation, the prevalence of xerostomia ranged from 0.9% to 64.8%. The majority of data collected for these studies was in Scandinavia (most patients age greater than 50, the rest being over 18).

Key benefits of the report:

1.The Xerostomia market report covers a descriptive overview and comprehensive insight of the Xerostomia epidemiology and Xerostomia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.The Xerostomia market report provides insights into the current and emerging therapies.

3.Xerostomia market report provides a global historical and forecasted market covering drug outreach in 7MM.

4.The Xerostomia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Xerostomia market.

Request for sample pages: https://www.delveinsight.com/sample-request/xerostomia-market

Xerostomia: Overview

Xerostomia is defined as the “complaint of oral dryness”. It can occur due to inadequate salivary secretion secondary to abnormal function of the salivary glands, which is categorized as “true” xerostomia; however, most patients with xerostomia often do not have objective signs of hyposalivation.“Symptomatic” xerostomia or “pseudo” xerostomia refers to oral dryness despite normal salivary gland function.

Patients with xerostomia can have clinical manifestations of difficulty in swallowing, chewing, and/or speaking and can present with a burning mouth, halitosis, altered taste, dry buccal mucosa, glossitis, cracked and peeled lips, oral candidiasis, and dental caries despite good oral hygiene.

The key players involved in the Xerostomia market:

Lubris BioPharma
MeiraGTx

The launch of the emerging therapies is expected to significantly impact the Xerostomia treatment scenario in the upcoming years:-

Drug covered

LBS020
AAV-AQP1

Request a free sample report @https://www.delveinsight.com/sample-request/xerostomia-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Xerostomia Patient Share (%) Overview at a Glance

5. Xerostomia Market Overview at a Glance

6. Xerostomia Disease Background and Overview

7. Xerostomia Epidemiology and Patient Population

8. Country-Specific Patient Population of Xerostomia

9. Xerostomia Current Treatment and Medical Practices

10. Unmet Needs

11. Xerostomia Emerging Therapies

12. Xerostomia Market Outlook

13. Country-Wise Xerostomia Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Xerostomia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Xerostomia-Pipeline Insights, 2021

"Xerostomia-Pipeline Insight, 2021" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Xerostomia market. A detailed picture of the Xerostomia pipeline landscape is provided, which includes the disease overview and Xerostomia treatment guidelines.

Xerostomia-Epidemiology Forecast to 2030

DelveInsight's 'Xerostomia-Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Xerostomia{;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Venous Thromboembolism (VTE) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP

DelveInsight's "Venous Thromboembolism - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Venous Thromboembolism, historical and forecasted epidemiology as well as the Venous Thromboembolism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on "Venous Thromboembolism (VTE)-Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Venous Thromboembolism (VTE)–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of Venous Thromboembolism (VTE), historical and forecasted epidemiology as well as the Venous Thromboembolism (VTE) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

As per the research study, Thromboembolism has a significant impact on morbidity and mortality internationally. A multinational report of European Union countries estimated that the total number of symptomatic, nonfatal VTE events per annum was more than 465,000 cases of DVT and more than 295,000 cases of PE.
Incidence found that 16,096 and 24,538 individuals in Japan were diagnosed with new PE and DVT, respectively, during 2011, which represented overall annual incidences of 12.6 and 19.2 per 100,000, respectively.
According to the research study incidence of first-time symptomatic VTE directly standardized for age and sex to the United States population ranged from 71 to 117 cases per 100,000 population. Approximately one-third of patients with symptomatic VTE manifest pulmonary embolism (PE), whereas two-thirds manifest deep vein thrombosis (DVT) alone.

Key benefits of the report:

1.The Venous Thromboembolism (VTE) market report covers a descriptive overview and comprehensive insight of the Venous Thromboembolism (VTE) epidemiology and Venous Thromboembolism (VTE) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.The Venous Thromboembolism (VTE) market report provides insights into the current and emerging therapies.

3.Venous Thromboembolism (VTE) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4.The Venous Thromboembolism (VTE) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Venous Thromboembolism (VTE) market.

Request for sample pages: https://www.delveinsight.com/sample-request/venous-thromboembolism-market

Venous Thromboembolism (VTE): Overview

Venous Thromboembolism (VTE) is a disorder that includes Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A deep vein thrombosis (DVT) occurs when a blood clot forms in a deep vein, usually in the lower leg, thigh, or pelvis. A deep vein thrombosis may occur if the flow of blood slows down in the body’s deep veins. A pulmonary embolism (PE) occurs when a clot breaks loose and travels through the bloodstream to the lungs.

The leading risk factor for VTE is long-term hospitalization, and the risk is high in patients with respiratory and circulatory system complications. The most common types of surgery associated with VTE are orthopedic surgeries, especially knee and hip replacements.

The key players involved in the Venous Thromboembolism (VTE) market:

Bayer Pharmaceuticals
Bristol-Myers Squibb/Janssen Pharmaceuticals
Quercis Pharma
Ono Pharmaceuticals
Verseon Corporation

The launch of the emerging therapies is expected to significantly impact the Venous Thromboembolism (VTE) treatment scenario in the upcoming years:-

Drug covered

Osocimab (BAY 1213790)
Milvexian (JNJ-70033093; BMS-986177)
Isoquercetin
ONO-7684
VE-1902

Request a free sample report @ https://www.delveinsight.com/sample-request/venous-thromboembolism-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Venous Thromboembolism (VTE) Patient Share (%) Overview at a Glance

5. Venous Thromboembolism (VTE) Market Overview at a Glance

6. Venous Thromboembolism (VTE) Disease Background and Overview

7. Venous Thromboembolism (VTE) Epidemiology and Patient Population

8. Country-Specific Patient Population of Venous Thromboembolism (VTE)

9. Venous Thromboembolism (VTE) Current Treatment and Medical Practices

10. Unmet Needs

11. Venous Thromboembolism (VTE) Emerging Therapies

12. Venous Thromboembolism (VTE) Market Outlook

13. Country-Wise Venous Thromboembolism (VTE) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Venous Thromboembolism (VTE) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Venous Thromboembolism (VTE)-Pipeline Insights, 2021

"Venous Thromboembolism (VTE)-Pipeline Insight, 2021" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Venous Thromboembolism (VTE) market. A detailed picture of the Venous Thromboembolism (VTE) pipeline landscape is provided, which includes the disease overview and Venous Thromboembolism (VTE) treatment guidelines.

Venous Thromboembolism (VTE)-Epidemiology Forecast to 2030

DelveInsight's 'Venous Thromboembolism (VTE)-Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Venous Thromboembolism (VTE){;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Small Fiber Neuropathy Market, Symptoms and Treatment Market

“Small Fiber Neuropathy Market” has been added to DelveInsight

Small Fiber Neuropathy Overview

Small Fiber Neuropathy (SFN) is a condition that generally affects the nervous system and is marked by severe pain attacks. It occurs when damage to the peripheral nerves predominantly or entirely affects the small myelinated (Aδ) fibers or unmyelinated C fibers thus called as Small Fiber Peripheral Neuropathy. It generally affects the small nerve fibers present in the skin and those responsible to mediate pain and thermal sensation. The specific fiber types involved in this process include both small somatic and autonomic fibers.

Small Fiber Neuropathy Market: Forecast

DelveInsight's "Small Fiber Neuropathy (SFN) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Small Fiber Neuropathy (SFN) , historical and forecasted epidemiology as well as the Small Fiber Neuropathy (SFN) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan

Request free sample copy- https://www.delveinsight.com/sample-request/small-fiber-neuropathy-market

Small Fiber Neuropathy Market: Regions Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Small Fiber Neuropathy Market: Report

SFN is caused by mutations in the SCN9A or SCN10A gene. Both the gene instructs the production of the alpha subunit for the NaV1.7 sodium channel. The SCN9A gene mutations result in NaV1.7 sodium channels that do not close completely when the channel is turned off and many SCN10A gene mutations results in opening of NaV1.8 sodium channels that more easily than usual. This increase in sodium ions enhances transmission of pain signals, causing individuals to be more sensitive to stimulation.

SFN is mainly associated with autoimmune diseases, sodium channel gene variants, diabetes mellitus, and vitamin B12 deficiencies, although in more than one-half of patients no etiology can be identified. Based on these etiologies, it can be divided in to four sub-groups such as Acquired SFN, Hereditary SFN, Syndromic SFN, and Idiopathic SFN.

Small Fiber Neuropathy Market: Symptoms

The symptoms of SFN include bowel problems, urinary issues, rapid heartbeat, abnormal sweating, and dry eyes and mouth. It is generally characterized by severe pain attacks that begin in the feet or hands.

Small Fiber Neuropathy Key Strengths

11 Year Forecast
7MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition
Small Fiber Neuropathy Market Size by Country
Small Fiber Neuropathy Market Size by Therapy

Small Fiber Neuropathy Market: Treatment

There is no cure for SFN. The frequency of SFN is not clearly known and it can vary according to ethnicity and gender. The progressiveness of this disease and its complications cause debilitating effects on the health of patients and impose a significant burden, both economically and on the quality of life. Thus, a lot of research has been done in this space to find the ways to manage the disease. Pain management and other symptomatic therapies are main components of the treatment system for patients with neuropathy. Non-pharmacological therapies such as transcutaneous electrical nerve stimulation, acupuncture, physical therapy and massage, and others are also used.

Small Fiber Neuropathy Market: Insights

Head-to-head trials of medications and long-term outcome data for small fiber neuropathies are lacking. When possible, disease-specific treatment guidelines should be selected for management of pain in small fiber neuropathy (e.g., diabetes, HIV, or chemotherapy). At present, therapeutic strategies are largely symptomatic. Three main categories of drugs are most commonly used for treating neuropathic pain: antidepressants, anti-epileptics, and opioids.

Small Fiber Neuropathy Market: Key Players

Vertex Pharmaceuticals
Biogen
And Many others

Small Fiber Neuropathy Market: Drugs

BIIB074
VX-150
And many others

Table of content

Key Insights
Executive Summary of Small Fiber Neuropathy (SFN)
Competitive Intelligence Analysis for Small Fiber Neuropathy (SFN)
Small Fiber Neuropathy (SFN) : Market Overview at a Glance
Small Fiber Neuropathy (SFN) : Disease Background and Overview
Patient Journey
Small Fiber Neuropathy (SFN) Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Unmet Needs
Key Endpoints of Small Fiber Neuropathy (SFN) Treatment
Marketed Products
Emerging Therapies
Small Fiber Neuropathy (SFN) : Seven Major Market Analysis
Attribute analysis
7MM: Market Outlook
Access and Reimbursement Overview of Small Fiber Neuropathy (SFN)
KOL Views
Market Drivers
Market Barriers
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

Why should you buy this report?

The report will help in developing business strategies by understanding trends shaping and driving the Small Fiber Neuropathy (SFN) market
To understand the future market competition in the Small Fiber Neuropathy (SFN) market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Small Fiber Neuropathy (SFN) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Small Fiber Neuropathy (SFN) market
To understand the future market competition in the Small Fiber Neuropathy (SFN) market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Generalized Pustular Psoriasis Market, Symptoms and Treatment Market by DelveInsight

“Generalized Pustular Psoriasis Market” has been added to DelveInsight

Generalized Pustular Psoriasis Overview

Generalized Pustular Psoriasis (GPP) is a subtype of pustular psoriasis characterized by painful and occasionally disfiguring cutaneous manifestations with sepsis-like systemic symptoms. Psoriasis is an immune-mediated disease being characterized by red scaly patches on the skin. It is clinically classified into two groups: pustular and non-pustular lesions.

Generalized Pustular Psoriasis Market Insights

The Generalized Pustular Psoriasis market report provides an understanding of the epidemiology and changing market dynamics of Generalized Pustular Psoriasis (GPP) in the seven major pharmaceutical markets for the period 2017–2030

Get a free Generalized Pustular Psoriasis market report sample page- https://www.delveinsight.com/sample-request/generalized-pustular-psoriasis-gpp-market

Generalized Pustular Psoriasis Market: Regions Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Generalized Pustular Psoriasis Market: Symptoms

Generalized pustular psoriasis has been associated with abnormalities in the cytokine (messenger protein) interleukin-36 receptor-antagonist signaling. This is due to recessive IL36RN gene mutations systemic symptoms and systemic upset.

Generalized Pustular Psoriasis Market: Report

Non-pustular psoriasis is further subdivided into Psoriasis vulgaris (early and late onset), Guttate psoriasis, Erythrodermic psoriasis, Palmoplantar psoriasis, Psoriatic arthritis (PsA), and Inverse psoriasis. The Pustular variant of the psoriasis is further subdivided into generalized and localized forms. The generalized form of pustular psoriasis is a potentially life-threatening, multisystemic inflammatory disease characterized by sudden, repeated episodes of high-grade fever, generalized erythematous pustular rashes, painful and occasionally disfiguring cutaneous manifestations with sepsis-like.

Generalized Pustular Psoriasis Treatment

The current therapeutic landscape of GPP in the United States is driven by supportive therapies (topical therapies, systemic therapies, biologics, and phototherapy). In EU-5 countries, for GPP, the market is the same as that of the US, with prescriptions for supportive therapies, due to lack of approved treatment regimens. In contrast to the US and EU-5 countries, the current therapeutic landscape of GPP in Japan is driven by a number of approved therapies, along with supportive treatment regimens.

Generalized Pustular Psoriasis Key Strengths

11 Year Forecast
7MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition
Market Size by Country
Market Size by Therapy

Key companies of the report

Janssen Pharmaceuticals
Novartis
Kyowa Hakko Kirin
AbbVie/Boehringer Ingelheim
AbbVie/Eisai
Eli Lilly & Company

Generalized Pustular Psoriasis Market Size

The dynamics of the GPP market are anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2020–2030. With this, several companies have shifted their focus toward this therapeutic area, and two of the therapies are expected to enter the treatment market of GPP during our forecast period, namely BI 655130 (Boehringer Ingelheim) and Imsidolimab (ANB019) (AnaptysBio).

Table of content

Key Insights
Generalized Pustular Psoriasis (GPP): Market Overview at a Glance
Generalized Pustular Psoriasis (GPP): Disease Background and Overview
Epidemiology and Patient Population
United States Epidemiology
EU5 Epidemiology
Japan Epidemiology
Treatment Algorithm, Current Treatment, and Medical Practices
Proposed Guidelines for the Diagnosis and Treatment of GPP
Unmet Needs
Marketed Products
Emerging Therapies
GPP: 7MM Market Analysis
United States: Market Outlook
EU-5 countries: Market Outlook
Japan Market Outlook
Market Drivers
Market Barriers
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

Generalized Pustular Psoriasis Key benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Generalized Pustular Psoriasis market
Organize sales and marketing efforts by identifying the best opportunities for Generalized Pustular Psoriasis market
To understand the future market competition in the GPP market.

Why should you buy this report?

The report will help in developing business strategies by understanding trends shaping and driving the Generalized Pustular Psoriasis market
To understand the future market competition in the Generalized Pustular Psoriasis market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Generalized Pustular Psoriasis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Generalized Pustular Psoriasis market
To understand the future market competition in the Generalized Pustular Psoriasis market

About Us

Celiac Disease Market Insights, Epidemiology and Market Forecast by DelveInsight

“Celiac Disease Market” has been added to DelveInsight

Celiac Disease Overview

Chronic kidney disease (CKD) is a syndrome where there are persistent alterations in kidney structure, function, or both with implications on the health of the individual. Examples of structural abnormalities include cysts, tumors, malformations and atrophy, which are evident on imaging. By contrast, kidney dysfunction can manifest as hypertension, edema, and changes in output or quality of urine and growth delay in children. These changes are most often recognized by increased serum levels of creatinine, cystatin C, or blood urea nitrogen. Moreover, the most common pathological manifestation of CKD, regardless of the initiating insult or disease, is some form of renal fibrosis.

Celiac Disease Market Insights

DelveInsight’s ‘Celiac Disease Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Celiac Disease (CD), historical and forecasted epidemiology as well as the Celiac Disease (CD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Get a free Celiac Disease report sample page- https://www.delveinsight.com/sample-request/celiac-disease-cd-market

Celiac Disease Market: Regions Covered

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Celiac Disease Market Report

Research Analysis
Market Analysis
Pipeline Valuation
Market Size by therapies
Market Share by therapies

Celiac Disease Treatment

Chronic kidney disease (CKD) is a type of kidney disease in which there is a gradual loss of kidney function over a period of months to years. The initial symptoms include leg swelling, feeling tired, vomiting, loss of appetite, and confusion; complications in CKD involve anemia, bone disease, high blood pressure and increased risk of heart disease. Anemia is common and is especially prevalent in those requiring hemodialysis. The mechanism of anemia in CKD are multifactorial and include increased inflammation, reduction in erythropoietin, and hyperuricemia leading to bone marrow suppression. There are different types of medications available in the market. Available medicines cannot reverse CKD; however, they are used to treat complications and to slow further kidney damage.

Celiac Disease Market: Key Players

GlaxoSmithKline
Akebia Therapeutics
AstraZeneca
Chong Kun Dang Pharmaceuticals

Celiac Disease Market: Drugs

Latiglutenase
Larazotide

Celiac Disease Market Size

The increase in market size is a direct consequence of increasing prevalent population of Chronic Kidney Disease (CKD) patients in the 7MM, along with the expected entry of premium price asset such Anti-inflammatories, Prolyl hydroxylase and IL-6 inhibitors, which will have a significant impact on the market size. The market size of Chronic Kidney Disease (CKD) is anticipated to increase during the study period, 2017–2030.

Celiac Disease Market Insights

Table of content

1 Key Insights

2 Celiac Disease Market Overview at a Glance

3 Executive Summary of Celiac Disease (CD)

4 Disease Background and Overview: Celiac Disease

5 Algorithm for Diagnosis of CD

6 Diagnostic Guidelines by the European Society for the Study of Coeliac Disease (ESsCD)

7 Diagnostic Guidelines by the World Gastroenterology Organization (WGO)

8 Epidemiology and Patient Population: Key Findings

9 Country Wise-Epidemiology of Celiac Disease

10 Treatment

11 Treatment Algorithm for CD

12 Treatment Algorithm for CD by BMJ Best Practice

13 European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders

14 World Gastroenterology Organisation Global Guidelines for CD

15 Recognized Establishments

16 Unmet Needs

17 Emerging Drugs

18 Celiac Disease: 7 Major Market Analysis

19 The United States Market Outlook

20 EU-5 Countries: Market Outlook

21 Japan Market Outlook

22 KOL Reviews

23 Case Reports

24 Market Drivers

25 Market Barriers

26 SWOT Analysis

27 Appendix

28 DelveInsight Capabilities

29 Disclaimer

30 About DelveInsight

Why should you buy this report?

The report will help in creating business methodologies by understanding patterns forming and driving the Celiac Disease market
To comprehend the future market rivalry in the Celiac Disease market and Insightful survey of the key market drivers and hindrances
Sort out deals and promoting endeavors by recognizing the best open doors for Celiac Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
ID of solid impending parts in the market will help in formulating procedures that will help in advancing beyond contenders
Coordinate deals and showcasing endeavors by recognizing the best open doors for Celiac Disease market
To comprehend the future market rivalry in the Celiac Disease market

You can check our related reports-

About Us

Mydriasis Market: Industry Analysis, Symptoms, Treatment, Drugs and Key Companies by Delveinsight |Théa Laboratories, Omeros Corporation, Ocuphire Pharma and Others

Mydriasis Market

DelveInsight’s ‘Mydriasis Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Mydriasis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Some of Mydriasis Market Report facts are:

The market size of mydriasis is anticipated to be USD 174 million in 2020 during the study period, 2018–2030.
Among the European 5 countries, Spain had the lowest number of cases as 0.36 million procedures in 2020.
Japan had 0.47 million prevalent cases in 2020 which is expected to increase by 2030.
In 2020, cataract surgeries numbers in the US varied according to gender; such as 2.20 million and 1.46 million procedures for females and males, respectively.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/mydriasis-market

Some of Mydriasis Companies are:

Théa Laboratories
Omeros Corporation
Ocuphire Pharma
And Many Others

Mydriasis is the dilation of the pupil, which may be due to a non-physiological cause such as disease, trauma, drug usage, or physiological pupillary response. A mydriatic is an agent that induces dilation of the pupil; it is routinely used to aid examination of the retina and other deep structures of the eye. In general medical practice, the most frequent indication for pupil dilation is in the screening of diabetic retinopathy followed by macular degeneration.

This condition can be a symptom of an injury to the brain from physical trauma or a stroke and can affect one pupil at a time or both at once. The pupillary dilation pathway is controlled by the iris dilator muscle, which consists of fibers that are oriented radially, and connect the exterior of the iris with the interior. When the dilator muscle contracts, it pulls the interior of the iris outward, thus increasing the size of the pupil. Furthermore, the iris dilator muscle is controlled by the sympathetic nervous system, the part of the autonomic nervous system that is involved in arousal, wakefulness, and the fight or flight response.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/mydriasis-market

Some of Mydriasis Therapies are:

Mydrane
OMIDRIA
Mydriasert
Nyxol
And Many Others

Scope of the Mydriasis Report:

The report covers the descriptive overview of mydriasis, explaining its causes, signs and symptoms, physiology and currently available therapies
Comprehensive insight has been provided into the Mydriasis epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for mydriasis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Mydriasis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Mydriasis market

Request for Free Sample Report: https://www.delveinsight.com/sample-request/mydriasis-market

Table of Contents:

1 Key Insights

2 Executive summary

3 Organizations

4 Epidemiology and Market Methodology

5 Mydriasis: Market Overview at a Glance

6 Mydriasis: Market Overview at a Glance

7 Epidemiology and Patient Population

8 Achieving Mydriasis

9 Unmet Needs

10 Marketed drugs

10.1 Mydrane: Théa Laboratories

10.2 Mydriasert: Théa Laboratories

10.3 OMIDRIA: Omeros Corporation

11 Emerging Therapies

11.2 Nyxol: Ocuphire Pharma

12 Mydriasis: Seven Major Market Analysis

13 Seven Major Market Outlook

14 United States Market Size

15 Market Drivers

16 Market Barriers

17 SWOT Analysis

18 Reimbursement policies

19 Case Study

20 KOL Views

21 Appendix

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

25 Bibliography

Request for Detailed TOC: https://www.delveinsight.com/sample-request/mydriasis-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/mydriasis-market